Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Shaw

Showing results (141-150 of 142) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 142 results.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Nature Structural & Molecular Biology|September 8, 2012
In support of the BMRBJohn L Markley, Hideo Akutsu, Tetsuo Asakura, et al.
Pageof 15

Showing results (141-150 of 142) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 142 results.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Nature Structural & Molecular Biology|September 8, 2012
In support of the BMRBJohn L Markley, Hideo Akutsu, Tetsuo Asakura, et al.
Pageof 15